Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.

被引：0

作者：

Hogdal, Leah ^{[1
]}

Chyla, Brenda ^{[2
]}

McKeegan, Evelyn ^{[2
]}

Leverson, Joel ^{[2
]}

Potluri, Jalaja ^{[2
]}

Humerickhouse, Rod ^{[2
]}

Mack, Mabry ^{[3
]}

DeAngelo, Daniel ^{[1
]}

Galinsky, Ilene ^{[1
]}

Stone, Richard ^{[1
]}

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] AbbVie Inc, N Chicago, IL USA

[3] AbbVie Inc, Redwood City, CA USA

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷

关键词：

D O I：

10.1158/1557-3265.HEMMAL14-B10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B10

引用

页数：2

共 50 条

[41] Overexpression of BCL-2 as a possible mechanism of chemoresistance in immature acute myeloid leukemia.
Venditti, A
DelPoeta, G
Aronica, G
Buccisano, F
Tamburini, A
Bruno, A
CoxFroncillo, MC
DelMoro, B
Epiceno, A
Amadori, S
BLOOD, 1997, 90 (10) : 289 - 289
[42] Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
Pallis, Monica
Burrows, Francis
Ryan, Jeremy
Grundy, Martin
Seedhouse, Claire
Abdul-Aziz, Amina
Montero, Joan
Letai, Anthony
Russell, Nigel
ONCOTARGET, 2017, 8 (10) : 16220 - 16232
[43] BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
C Touzeau
J Ryan
J Guerriero
P Moreau
T N Chonghaile
S Le Gouill
P Richardson
K Anderson
M Amiot
A Letai
Leukemia, 2016, 30 : 761 - 764
[44] ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+-signalling dysregulation or toxicity in pancreatic acinar cells
Jakubowska, Monika A.
Kerkhofs, Martijn
Martines, Claudio
Efremov, Dimitar G.
Gerasimenko, Julia V.
Gerasimenko, Oleg V.
Petersen, Ole H.
Bultynck, Geert
Vervliet, Tim
Ferdek, Pawel E.
BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (22) : 4402 - 4415
[45] BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
Touzeau, C.
Ryan, J.
Guerriero, J.
Moreau, P.
Chonghaile, T. N.
Le Gouill, S.
Richardson, P.
Anderson, K.
Amiot, M.
Letai, A.
LEUKEMIA, 2016, 30 (03) : 761 - 764
[46] A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)
Konopleva, Marina
Pollyea, Daniel A.
Potluri, Jalaja
Chyla, Brenda J.
Busman, Todd
McKeegan, Evelyn
Salem, Ahmed
Zhu, Ming
Ricker, Justin L.
Blum, William
DiNardo, Courtney D.
Dunbar, Martin
Kirby, Rachel
Falotico, Nancy
Leverson, Joel D.
Humerickhouse, Rod A.
Mabry, Mack
Stone, Richard M.
Kantarjian, Hagop M.
Letai, Anthony G.
BLOOD, 2014, 124 (21)
[47] Clinical relevance of flow cytometric BCL-2 and CD95 expression in acute myeloid leukemia.
Kutlay, S
Beksac, M
Dalva, K
Ilhan, O
Akan, H
Koc, H
Ozcan, M
Konuk, N
Uysal, A
BLOOD, 1997, 90 (10) : 3709 - 3709
[48] Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
Zhao, Jianyun
Niu, Xiaojia
Li, Xinyu
Edwards, Holly
Wang, Guan
Wang, Yue
Taub, Jeffrey W.
Lin, Hai
Ge, Yubin
ONCOTARGET, 2016, 7 (23) : 34785 - 34799
[49] Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
Luedtke, Daniel A.
Niu, Xiaojia
Pan, Yihang
Zhao, Jianyun
Liu, Shuang
Edwards, Holly
Chen, Kang
Lin, Hai
Taub, Jeffrey W.
Ge, Yubin
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
[50] Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells
Zhao, Jianyun
Niu, Xiaojia
Edwards, Holly
Wang, Yue
Taub, Jeffrey W.
Lin, Hai
Ge, Yubin
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →